Thursday, April 19, 2012

Daiichi Sankyo Leverages its hybrid model to launch Sevikar in Romania

Daiichi Sankyo will be launching in Romania - a fixed dose combination of  Olmesartan medoxmil and almodipine besylate - Sevikar for the treatment of hypertension through Ranbaxy's subsidiary, Terapia. The FDC is expected to be included in the national lists of compensated drugs.  This is the third product which has been introduced under the hybrid model.